Join us on the latest episode! Our Guest: Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation.

What you'll get out of this episode:

• PDS Biotechnology targets the key limitations of CAR T and cancer vaccine therapies using lipid nanoparticle-based immunotherapy.
• Their lead candidate, PDS0101, demonstrated over 2x improvement in survival for HPV-positive head and neck cancer.
• The platform technology shows consistent efficacy across multiple independent Phase 2 trials.
• Late-stage clinical programs focus on HPV16+ head and neck cancer, with additional trials for colorectal, prostate, and MUC1+ cancers.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/frank-bedu-addo-4797947/
Company LinkedIn https://www.linkedin.com/company/pds-biotechnology-corporation/
Website https://www.pdsbiotech.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/